Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2006

View Archived Issues

MCB-3837 and MCB-3681 yield promising results against Gram-positive strains

Dong-A expects to commence phase I development of DA-7218 in 2006

Bristol-Myers Squibb completes rolling NDA for dasatinib

YM-477: new orally active TPO agonist

Johnson & Johnson and Guidant merger statement declared effective

Candidate drug selected in Medivir's HCV collaboration with Tibotec

Phase IIa study begins for topical PTH (1-34)

Update on Maxim and EpiCept merger

sanofi-aventis and Regeneron amend VEGF Trap agreement

NitroMed and Boston Scientific conclude research collaboration

Novel agents for treating neurodegenerative disorders disclosed in recent Migenix patent

Recent patents cover novel treatment options for cancer

Novel agents with potential for the treatment of anxiety, depression, etc.

Further studies of NPI-0052 presented

New histamine H3 receptor ligands emerge from Banyu R&D

Primary endpoint data from phase II/III trial for Dynavax's Heplisav

LY-517717: A novel prophylactic for VTE following major orthopedic surgery

FDA approval for Vaprisol in euvolemic hyponatremia

EDO-P4 demonstrates broad antifungal activity

Genentech submits BLA for Lucentis in wet AMD

Data from several lenalidomide studies presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...